Literature DB >> 10456908

The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody.

R M Syme1, T F Bruno, T R Kozel, C H Mody.   

Abstract

Cell-mediated immunity is critical for the host defense to Cryptococcus neoformans, as demonstrated by numerous animal studies and the prevalence of the infection in AIDS patients. Previous studies have established that the polysaccharide capsule contributes to the virulence of C. neoformans by suppressing T-lymphocyte proliferation, which reflects the clonal expansion of T lymphocytes that is a hallmark of cell-mediated immunity. The present studies were performed to identify the major mechanism by which polysaccharide impairs lymphocyte proliferation, since capsular polysaccharide has the potential to affect the development of T-lymphocyte responses by stimulating production of interleukin-10 (IL-10), inhibiting phagocytosis, and inducing shedding of cell surface receptors. We demonstrate that polysaccharide inhibits lymphocyte proliferation predominantly by blocking uptake of C. neoformans, which is crucial for subsequent lymphocyte proliferation. In addition, we show that polysaccharide did not suppress lymphocyte proliferation via an IL-10-dependent mechanism, nor did it affect critical surface receptor interactions on the T cell or antigen-presenting cell. Having established that polysaccharide impairs phagocytosis, we performed studies to determine whether opsonization with human serum or with anticapsular antibody could reverse this effect. Impaired uptake and lymphocyte proliferation that were induced by polysaccharide can be enhanced through opsonization with monoclonal antibodies or human serum, suggesting that antipolysaccharide antibodies might enhance the host defense by restoring uptake of the organism and subsequent presentation to T lymphocytes. These studies support the therapeutic potential of stimulating cell-mediated immunity to C. neoformans with anticapsular antibody.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456908      PMCID: PMC96786          DOI: 10.1128/IAI.67.9.4620-4627.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Cryptococcal infection in AIDS.

Authors:  R J Coker
Journal:  Int J STD AIDS       Date:  1992 May-Jun       Impact factor: 1.359

2.  Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide.

Authors:  C Spiropulu; R A Eppard; E Otteson; T R Kozel
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

3.  T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice.

Authors:  R R Yuan; A Casadevall; J Oh; M D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

4.  Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes.

Authors:  S F Davies; D P Clifford; J R Hoidal; J E Repine
Journal:  J Infect Dis       Date:  1982-06       Impact factor: 5.226

5.  Impairment of raw 264.7 macrophage function by antiarrhythmic drugs.

Authors:  K C Das; H P Misra
Journal:  Mol Cell Biochem       Date:  1994-03-30       Impact factor: 3.396

6.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Authors:  J Mukherjee; L S Zuckier; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses.

Authors:  H L Collins; G J Bancroft
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  Binding of cryptococcal polysaccharide to Cryptococcus neoformans.

Authors:  T R Kozel; C A Hermerath
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

9.  Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans.

Authors:  C H Mody; R M Syme
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

10.  Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.

Authors:  D C Houpt; G S Pfrommer; B J Young; T A Larson; T R Kozel
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

View more
  33 in total

1.  Does the Capsule Interfere with Performance of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Cryptococcus neoformans and Cryptococcus gattii?

Authors:  Danilo Y Thomaz; Rafaella C Grenfell; Monica S M Vidal; Mauro C Giudice; Gilda M B Del Negro; Luiz Juliano; Gil Benard; João N de Almeida Júnior
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

2.  Loss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of Cryptococcus neoformans.

Authors:  Neena Jain; Li Li; Ye-Ping Hsueh; Abraham Guerrero; Joseph Heitman; David L Goldman; Bettina C Fries
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

3.  Cryptococcus neoformans-induced macrophage lysosome damage crucially contributes to fungal virulence.

Authors:  Michael J Davis; Alison J Eastman; Yafeng Qiu; Brian Gregorka; Thomas R Kozel; John J Osterholzer; Jeffrey L Curtis; Joel A Swanson; Michal A Olszewski
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

4.  Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.

Authors:  Luis R Martinez; Arturo Casadevall
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection.

Authors:  B C Fries; C P Taborda; E Serfass; A Casadevall
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

6.  A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide.

Authors:  M Piccioni; C Monari; S Bevilacqua; S Perito; F Bistoni; T R Kozel; A Vecchiarelli
Journal:  Clin Exp Immunol       Date:  2011-05-23       Impact factor: 4.330

Review 7.  How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts.

Authors:  Steven T Denham; Morgan A Wambaugh; Jessica C S Brown
Journal:  J Mol Biol       Date:  2019-05-09       Impact factor: 5.469

8.  Surfactant protein D increases phagocytosis of hypocapsular Cryptococcus neoformans by murine macrophages and enhances fungal survival.

Authors:  Scarlett Geunes-Boyer; Timothy N Oliver; Guilhem Janbon; Jennifer K Lodge; Joseph Heitman; John R Perfect; Jo Rae Wright
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

Review 9.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

10.  Phenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host response.

Authors:  Abraham Guerrero; Bettina C Fries
Journal:  Infect Immun       Date:  2008-06-30       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.